Free tool
FAERS Monitor: Cabtreo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216632 or its brand name (Cabtreo, Adapalene, Benzoyl Peroxide, Clindamycin Phosphate). Reports on generic versions are filed under their own applications.
Reports
60
Serious
8
13% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- application site pain7
- drug hypersensitivity6
- application site dryness5
- drug ineffective5
- application site pruritus4
- application site erythema3
- erythema3
- hypersensitivity3
- pain3
- product use issue3
- pruritus3
- accidental exposure to product2
- acne2
- application site irritation2
- burning sensation2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 14 |
| 2025 | 31 |
| 2026 | 15 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,099 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site drynessSignal | 5 | 517.1 | 223.3 | 2,083 |
| application site painSignal | 7 | 111.4 | 55.5 | 660 |
| application site pruritusSignal | 4 | 61.8 | 24.0 | 183 |
| application site irritation | 2 | 56.4 | 14.4 | 60 |
| application site erythemaSignal | 3 | 40.1 | 13.3 | 79 |
| drug hypersensitivitySignal | 6 | 10.9 | 5.1 | 45 |
| burning sensation | 2 | 10.0 | 2.6 | 8 |
| acne | 2 | 9.2 | 2.4 | 8 |
| accidental exposure to product | 2 | 6.8 | 1.7 | 5 |
| hypersensitivitySignal | 3 | 5.7 | 1.9 | 7 |
| product use issueSignal | 3 | 5.6 | 1.9 | 7 |
| erythemaSignal | 3 | 5.1 | 1.7 | 6 |
| pruritus | 3 | 2.7 | 0.9 | 2 |
| pain | 3 | 1.7 | 0.6 | 0 |
| drug ineffective | 5 | 1.3 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.